GROW focuses on research and teaching of genetic and cellular mechanisms, as well as environmental and life-style factors that underlie normal (embryonic and fetal) and abnormal (cancer) growth. The emphasis is on basic and translational research, aiming at innovative approaches for individualizing prevention, patient diagnosis, and treatment for genetically determined diseases and cancer.
More and more is possible in the field of breast reconstruction after cancer surgery. For example, a breast can be made with your own tissue that looks very natural. However, there will be less feeling in the new breast. This has never really been addressed. And yet, an increasing number of women say that they miss that 'old' feeling very much.
Dr Stefania Tuinder wants to contribute to the recovery of a reconstructed breast that feels as "normal" as possible. She has been a plastic surgeon at Maastricht UMC+ since 2007. Dr Tuinder: "The Netherlands is a leader in the field of breast reconstruction. We can achieve very good results, but unfortunately not for every woman. That's why I've been doing research in the field of breast reconstruction for years.'
In 2021, Lizza Hendriks, Assistant Professor at research institute GROW, School for Oncology and Developmental Biology of Maastricht University will join The Young Academy. This is a platform of the Royal Netherlands Academy of Sciences, where young top scientists from different disciplines work together in the field of research and science policy.
Dr Lizza Hendriks (1981) has worked at Maastricht UMC + as a lung specialist since 2012. Her focus area is thoracic oncology, in particular prevention and optimal treatment of brain metastases in lung cancer. In 2016, she earned her PhD on this topic. To gain in-depth knowledge of both research and medical oncology, she worked one year as a postdoc at the Gustave Roussy Institute in France.
Since 2019, Dr Hendriks has coordinated the clinical lung cancer research of the lung diseases department in Maastricht. She does this in addition to her clinical tasks and teaching. Currently, Dr Hendriks supervises six PhD students.
Her research ambition is to develop personalised therapy (in terms of biomarkers and psychosocial and cognitive capacity) with a focus on prevention/optimal treatment of brain metastases, while preserving neurocognition. To achieve this, immunotherapy, targeted therapy and radiotherapy are applied, including the use of advanced imaging analysis techniques such as radiomics.
Dr Hendriks received several abstract awards as well as the Dirkje Postma Talent Award (incentive subsidy for her own research line) in 2019. She is (co-)author of more than 80 peer-reviewed articles.
The Young Academy consists of talented researchers who share a broad interest in scientific practice, science policy and science communication. The Young Academy (De Jonge Akademie) is an independent body within the Royal Netherlands Academy of Sciences. Membership lasts for five years.
Within De Jonge Akademie, Lizza Hendriks is particularly committed to early career policy, getting young people interested in and motivated for research. She will also contribute to the new Recognition and Rewards policy, with a focus on policy for physician researchers.
Dear GROW member,
Did you miss our annual GROW Science Day ‘From basic science to clinical applications’ ?
Click on this link to look back.
Keynote speakers are René Bernards and Siladitya Bhattacharya.
Susanne Maris facilitated an online workshop on work-life balance in times of Corona-virus.
GROW research activities in the areas of oncology and developmental medicine are closely interrelated, revolving around the same basic concepts and research techniques. Scientists at GROW collaborate intensively with clinicians at the Maastricht Oncology Centre and the Centre for Genetics, Reproduction and Child Health.
An important aim within GROW is training master's and PhD students in the fields of modern medicine and molecular life sciences.
“Our results have been a wake-up call for IVF centers worldwide.”
“Ultimately, we want personal, tailor-made lifestyle advice for every cancer survivor who needs it.”
“We are repurposing a well-known malaria-drug for our fight against cancer.”
A radiation oncologist by training, Philippe Lambin does not limit his research to a single disease. His latest achievement: three European grants for his research on COVID-19.
GROW works in close cooperation with the Maastricht University Medical Center+ (MUMC+). MUMC+ is known both nationally and internationally for its focus on prevention and taking an integrated approach to health care: from prevention, promotion of good health, and basic care, to top-level clinical diagnostics and treatment. Patient safety is our top priority in all of our endeavours. MUMC+ is part of The Netherlands Federation of University Medical Centres.